Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95 | Zendy

Russell L. Basser | Zendy; Anne O’Neill | Zendy; Giovanni Martinelli | Zendy; Michael D. Green | Zendy; Fedro A. Peccatori | Zendy; Saverio Cinieri | Zendy; Alan S. Coates | Zendy; Richard D. Gelber | Zendy; Stefan Aebi | Zendy; Monica CastiglioneGertsch | Zendy; Guiseppe Viale | Zendy; Karen N. Price | Zendy; Aron Goldhirsch | Zendy

Open Access

Multicycle Dose-Intensive Chemotherapy for Women With High-Risk Primary Breast Cancer: Results of International Breast Cancer Study Group Trial 15-95

Author(s) -

Russell L. Basser,

Anne O’Neill,

Giovanni Martinelli,

Michael D. Green,

Fedro A. Peccatori,

Saverio Cinieri,

Alan S. Coates,

Richard D. Gelber,

Stefan Aebi,

Monica CastiglioneGertsch,

Guiseppe Viale,

Karen N. Price,

Aron Goldhirsch

Publication year - 2006

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2005.03.5196

Subject(s) - medicine , epirubicin , anthracycline , breast cancer , filgrastim , cyclophosphamide , hazard ratio , tamoxifen , chemotherapy , axillary lymph nodes , oncology , surgery , cancer , confidence interval , neutropenia

To compare adjuvant dose-intensive epirubicin and cyclophosphamide chemotherapy administered with filgrastim and progenitor cell support (DI-EC) with standard-dose anthracycline-based chemotherapy (SD-CT) for patients with early-stage breast cancer and a high risk of relapse, defined as stage II disease with 10 or more positive axillary nodes; or an estrogen receptor-negative or stage III tumor with five or more positive axillary nodes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research